Literature DB >> 19944888

The burden of depressive symptoms in people with schizophrenia.

Robert R Conley1.   

Abstract

People with schizophrenia and concurrent depressive symptoms have poorer long-term functional outcomes compared with the nondepressed. Their poorer quality of life, greater use of mental health services, and higher risk of involvement with law enforcement agencies underscore a need for special treatment interventions. Treatment of the nonpsychotic dimensions of schizophrenia is a critical part of recovery. In a 3-year study, the depressed cohort was significantly more likely than the nondepressed to use relapse-related mental health services (emergency psychiatric services, sessions with psychiatrists); to be a safety concern (violent, arrested, victimized, or suicidal); to have greater substance-related problems; and to report poorer life satisfaction, quality of life, mental functioning, family relationships, and medication adherence. Furthermore, changes in depressed status were associated with changes in functional outcomes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19944888     DOI: 10.1016/j.psc.2009.09.001

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  9 in total

1.  Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia.

Authors:  Y-T Xiang; G S Ungvari; C U Correll; H F K Chiu; N Shinfuku
Journal:  Epidemiol Psychiatr Sci       Date:  2015-08-20       Impact factor: 6.892

2.  Comorbid Moderate-Severe Depressive Symptoms and their Association with Quality of Life in Chinese Patients with Schizophrenia Treated in Primary Care.

Authors:  Cai-Lan Hou; Xin-Rong Ma; Mei-Ying Cai; Yan Li; Yu Zang; Fu-Jun Jia; Yong-Qiang Lin; Helen F K Chiu; Gabor S Ungvari; Brian J Hall; Bao-Liang Zhong; Xiao-Lan Cao; Yu-Tao Xiang
Journal:  Community Ment Health J       Date:  2016-06-15

3.  Association of APOE E2 and low-density lipoprotein with depressive symptoms in Chinese senile schizophrenia inpatients: A cross-sectional study.

Authors:  Wei Li
Journal:  Schizophr Res Cogn       Date:  2020-11-19

4.  The use of the theory of planned behavior to predict engagement in functional behaviors in schizophrenia.

Authors:  Brent T Mausbach; Raeanne C Moore; Taylor Davine; Veronica Cardenas; Christopher R Bowie; Jennifer Ho; Dilip V Jeste; Thomas L Patterson
Journal:  Psychiatry Res       Date:  2012-09-29       Impact factor: 3.222

5.  Affective lability and social functioning in severe mental disorders.

Authors:  Margrethe Collier Høegh; Ingrid Melle; Sofie R Aminoff; Stine Holmstul Olsen; Synve Hoffart Lunding; Torill Ueland; Trine Vik Lagerberg
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-01-27       Impact factor: 5.760

6.  Feasibility of using a smartphone app to assess early signs, basic symptoms and psychotic symptoms over six months: A preliminary report.

Authors:  Emily Eisner; Sandra Bucci; Natalie Berry; Richard Emsley; Christine Barrowclough; Richard James Drake
Journal:  Schizophr Res       Date:  2019-04-09       Impact factor: 4.939

7.  Association between depressive symptoms and cognitive-behavioural therapy receipt within a psychosis sample: a cross-sectional study.

Authors:  Ava Mason; Jessica Irving; Megan Pritchard; Jyoti Sanyal; Craig Colling; David Chandran; Robert Stewart
Journal:  BMJ Open       Date:  2022-05-10       Impact factor: 3.006

8.  Atypical antipsychotics in the treatment of depressive and psychotic symptoms in patients with chronic schizophrenia: a naturalistic study.

Authors:  Marco Innamorati; Stefano Baratta; Cristina Di Vittorio; David Lester; Paolo Girardi; Maurizio Pompili; Mario Amore
Journal:  Schizophr Res Treatment       Date:  2013-01-21

9.  Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review.

Authors:  José M Olivares; Jan Sermon; Michiel Hemels; Andreas Schreiner
Journal:  Ann Gen Psychiatry       Date:  2013-10-23       Impact factor: 3.455

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.